Bellerophon Therapeutics (BLPH) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update
August 9, 2016 6:33 AM EDTWARREN, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today reported financial results for the second quarter ended June 30, 2016 and provided a business update.
This quarter, we made important progress on our development plans across our clinical pipeline, stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. As planned, in June we enrolled our first patient in our Phase 3 INOvation-1 clinical trial to treat Pulmonary Arterial Hypertension, or PAH, under an FDA-granted Special Protocol Assessment. We also commenced a trial with our INOpulse therapy to treat pulmonary... More
